Lupin Manufacturing Solutions (LMS), a subsidiary of global pharma major Lupin Limited, announced a long-term strategic alliance with PolyPeptide Group AG (PolyPeptide), a specialized, global CDMO for peptide-based active pharmaceutical ingredients.

This collaboration aims to enhance supply chain resilience, improve operational efficiency, and accelerate readiness for the rapidly expanding global peptides market. It also advances next-generation peptide therapeutics, including those for metabolics, supporting the long-term strategic growth of both organizations.

This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets, while enhancing PolyPeptide's position as a trusted CDMO partner.

Dr. Abdelaziz Toumi, Chief Executive Officer, Lupin Manufacturing Solutions, said, "We are delighted to announce our strategic alliance with PolyPeptide. As peptide-based therapies continue to transform the treatment landscape for metabolic and other chronic conditions, LMS is committed to ensuring reliable access to specialised materials that support large-scale commercial production. This underscores our mission to establish secure, agile, and future-ready supply pathways for innovators worldwide."

"Reliability is a competitive advantage in our industry. Working with Lupin Manufacturing Solutions gives us the flexibility and supply chain depth needed to support growing customer demand, including preparations for large-scale metabolics," said Stéphane Varray, Chief Commercial Officer, PolyPeptide. "When you're enabling life-changing therapies, your supply chain must operate as a true strategic capability."